Description overdue on 09.07.2012

Antiparkinsonian.   The main components are benserazide   and Levodopa . Laevorotatory isomer DOPA (levodopa) is a precursor of dopamine. Under its influence reduced severity dysphagia , Rigidity, hypokinesia, tremor and salivation .  Antiparkinsonian effect due to the conversion of levodopa in the central nervous system dopamine that helps compensate the shortage of dopamine in the nervous system .  A significant portion of the drug is converted to dopamine in peripheral tissues located, and has no effect on the disease, but increases the severity of side effects .  Inhibitor peripheral dopa-decarboxylase - benserazide reduces the amount of dopamine in peripheral tissues located, which indirectly increases the level of levodopa, which enters the central nervous system .  The optimal ratio of benserazide and levodopa is considered to be 4: 1 .  Sensible therapeutic effect observed after a week use of the drug Madopar .  Maximum efficiency is recorded in a month .  Due capsules GSS therapeutically effective drug concentration in blood plasma is created in a few hours and do not cause essential fluctuations .  Madopar available in tablet dosage form, in the form of capsules .

Indications, contraindications:

Madopar is used for Parkinson's disease, Parkinson's syndrome (except when caused by the use of antipsychotic drugs). Madopar is not indicated in case of intolerance benserazide, levodopa, with severe renal disease, hepatic, endocrine and cardiovascular systems. The drug is not used in the inhibition of bone marrow hematopoiesis, during pregnancy,   melanoma , Psychosis, breastfeeding, patients under 30 years. In osteomalacia, ulcerative lesions of the digestive system, arrhythmia, myocardial infarction Madopar used with caution.

Side effect:

In the first days of therapy with Madopar marked dysphagia, epigastric pain, loss of appetite, vomiting, nausea, ulcerogenic effects   in predisposed patients. Rarely recorded orthostatic hypotension , Arrhythmias. When long-term therapy are marked dyskinesia, hyperkinesia, spontaneous movement, thrombocytopenia, hemolytic anemia , Leucopenia, depression, irritability, insomnia, mental disorders, sleep disorders, weight gain, constipation Tachycardia.

Mode of application:

Dosing is carried out individually. Initial therapy: 0, 125 g (1 25 mg capsule contains 100 mg of levodopa and benserazide) twice a day. Weekly increased dosage of 1 capsule. When registering the side effects of the drug overturned. After their disappearance, increase the dose of 1 capsule per day, every 2 weeks. Madopar therapy is carried out for a long time. If during the day marked fluctuations in drug efficacy, then switch to the capsule REG gradual, slow release. Dose capsules GSS increased every 2-3 days. If no effect when taking the drug at a dose of 1, 5 grams per levodopa should go back to the reception of the usual form of medicament.

Special instructions:

Patients with glaucoma require regular monitoring of intraocular pressure indicator. Madopar tablets should be taken during meals or drinking plenty of fluids. The capsules are swallowed whole recommended. 3 days before the intended surgery under anesthesia Madopar overturned. Unacceptable abrupt withdrawal of the drug. It madopar affect the management of vehicles, execution of complex activities.

Drug Interactions:

The risk of heart rhythm disorders grows, while the appointment ditilina, beta-agonists , Medicines for inhalation anesthesia. Antiparkinsonian effect is reduced when taking thioxanthene, difenilbutilpiperidina, butyrophenone, neuroleptics, anticholinergics M, klozepina, diazepam, phenytoin, papaverine, pyridoxine, reserpine. Tricyclic antidepressants   reduce the bioavailability of the drug. Hallucinations and dyskinesia observed when taking lithium preparations. Methyldopa exacerbates the severity of side effects. Poor circulation,   tachycardia , Agitation, facial flushing, dizziness, increased blood pressure recorded when taking MAO inhibitors (due to the accumulation of norepinephrine and dopamine under the effect of levodopa). At reception tubocurarine   significantly increases the probability of falling blood pressure.